Konturek S J, Pawlik W, Mysh W, Gustaw P, Sendur R, Mikos E, Bielański W
Institute of Physiology, Academy of Medicine, Krakow, Poland.
Regul Pept. 1990 Sep 10;30(2):137-48. doi: 10.1016/0167-0115(90)90054-z.
Epidermal growth factor (EGF), which was originally identified in salivary glands and saliva, has been also found in the kidney and urine, suggesting that the kidney may be an alternate source of this peptide. Liver was considered as the major site of the degradation of EGF but the involvement of other organs has been little studied. Therefore, we carried out comparative studies on the organ uptake and the disappearance half-time of EGF and insulin (having similar molecular size) in the same model of anesthetized dog with arterial (from aorta) and venous (from mesenteric, portal, hepatic, renal, femoral and jugular veins) blood sampling from various organs. Basal plasma level of EGF (1.32 +/- 0.33 pmol/l) and insulin (62.1 +/- 13.8 pmol/l) in the aorta was not significantly different from that recorded at various sampling sites. During i.v. infusion of EGF at 41.6 and 166.6 pmol/kg/h, the respective arterial EGF concentrations averaged 103 +/- 21 and 240 +/- 49 pmol/kg/h and the percent reduction in plasma EGF after passage through the head, leg, intestines and liver was about 30-50% and that after passage through the kidney was about 95%. During insulin (6.9 pmol/kg/h) infusion, the arterial hormone level averaged 227 +/- 21 pmol/l and this level was significantly reduced (by 23-42%) after passage through the head, leg, intestine, liver and kidney but no significant difference was found between various venous sampling sites. EGF and insulin appearing in the urine during EGF or insulin infusion accounted for about 40 and 7% of the difference between the entering and leaving renal masses of the peptide. Mean disappearance half time on stopping of EGF and insulin infusion was, respectively, 2.32 +/- 0.58 and 6.88 +/- 1.25 min. We conclude that unlike insulin, which is removed to similar extent by various organs including the kidney and the liver, EGF is taken up mainly by kidney and EGF present in urine originates mainly from renal clearance of peptide.
表皮生长因子(EGF)最初是在唾液腺和唾液中发现的,在肾脏和尿液中也有发现,这表明肾脏可能是这种肽的另一个来源。肝脏被认为是EGF降解的主要部位,但其他器官的参与情况研究较少。因此,我们在麻醉犬的同一模型中,从主动脉和肠系膜、门静脉、肝静脉、肾静脉、股静脉和颈静脉等不同器官进行动脉血和静脉血采样,对EGF和胰岛素(分子大小相似)的器官摄取和消失半衰期进行了比较研究。主动脉中EGF的基础血浆水平(1.32±0.33 pmol/l)和胰岛素的基础血浆水平(62.1±13.8 pmol/l)与在各个采样部位记录的水平无显著差异。在以41.6和166.6 pmol/kg/h的速度静脉输注EGF期间,相应的动脉EGF浓度平均分别为103±21和240±49 pmol/kg/h,EGF通过头部、腿部、肠道和肝脏后血浆中EGF的降低百分比约为30 - 50%,通过肾脏后约为95%。在输注胰岛素(6.9 pmol/kg/h)期间,动脉激素水平平均为227±21 pmol/l,该水平在通过头部、腿部、肠道、肝脏和肾脏后显著降低(降低23 - 42%),但在各个静脉采样部位之间未发现显著差异。在输注EGF或胰岛素期间出现在尿液中的EGF和胰岛素分别占该肽进入和离开肾脏量差值的约40%和7%。停止输注EGF和胰岛素后的平均消失半衰期分别为2.32±0.58分钟和6.88±1.25分钟。我们得出结论,与胰岛素不同,胰岛素被包括肾脏和肝脏在内的各种器官以相似程度清除,而EGF主要被肾脏摄取,尿液中的EGF主要源于该肽的肾脏清除。